Study of CTX-471 in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, first-in-human study of CTX-471 monotherapy in patients with
metastatic or locally advanced malignancies that have progressed while receiving an approved
PD-1 or PD-L1 inhibitor. The study will be conducted in 2 parts: Part 1 Dose Escalation and
Part 2 Dose Expansion.